当前位置: 易推广 > 生物试剂/抗体/细胞 > 生化试剂 > 其他 > MedChemExpress > 产品展示 > MCE信号通路 > 蛋白偶联受体/G 蛋白 > Eprazi dihydrochloride
Eprazi dihydrochloride
企业档案
会员类型:会员
已获得易推广信誉 等级评定
(0 -40)基础信誉积累,可浏览访问
(41-90)良好信誉积累,可接洽商谈
(91+ )优质信誉积累,可持续信赖
易推广会员:8年
最后认证时间:
注册号: 【已认证】
法人代表: 【已认证】
企业类型:生产商 【已认证】
注册资金:人民币万 【已认证】
产品数:91194
参观次数:10500839
联系我们
MedChemExpress
电话:021-58955995
联系人:客服部 (请说明是在易推广看到的!谢谢)
手机:13611715263
邮编:201203
邮箱:sales@medchemexpress.cn
地址:上海上海
详细内容
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
Eprazi dihydrochloride
CAS No. : 10402-53-6
MCE 站:Eprazi dihydrochloride
产品活性:Eprazi dihydrochloride 是一种具有粘液溶解,分泌分解,镇咳和支气管解痉性质的药物。Eprazi dihydrochloride 是一种神经激肽 1 受体 (NK1R) 的配体。Eprazi dihydrochloride 可用于慢性支气管炎的研究,可改善肺功能和动脉血氧分压。
研究领域:GPCR/G Protein | Neuronal Signaling
作用靶点:Neurokinin Receptor
In Vitro: Eprazi specifically displaces binding to the NK1R. Although Eprazi displays a rather weak inhibition of [125I]BH-SP binding to NK1R, at a concentration of 25 μM, and an antagonistic effect of about 30%, NK1R blockade could contribute to its mucolytic activity.
In Vivo: Eprazi (50-200 mg/kg; oral gavage; daily; for 4 days; adult male rats) at a dose of 200 mg/kg significantly increases total and individual (with the exception of phosphatidylinositol) phospholipid levels and decreases total neutral lipids. Lower doses of Eprazi significantly decrease neutral lipid levels without affecting the phospholipids.
In airway epithelial studies, mucosal addition of Eprazi produces a dose-dependent partially reversible decrease in short-circuit current (Isc). The decrease in Isc at lower Eprazi concentrations is accounted for entirely by a decrease in net chloride secretion while at higher concentrations both sodium and chloride transport are affected.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | Bioactive Compound Library Plus | GPCR/G Protein Compound Library | Immunology/Inflammation Compound Library | Neuronal Signaling Compound Library | FDA-Approved Drug Library | Drug Repurposing Compound Library | NMPA-Approved Drug Library | Neurotransmitter Receptor Compound Library | FDA Approved & Pharmacopeial Drug Library | Substance P | Aprepitant | Netupitant | Senktide | Fosaprepitant dimeglumine | SB-222200 | Maropitant | Vapreotide | Neurokinin A TFA | Neurokinin B TFA | Saredutant | Talnetant | Vofopitant | L-732138 | NKP608 | [Sar9,Met(O2)11]-Substance P TFA | Y1 receptor antagonist 1 | Substance P(1-7) TFA | GR 159897 | Men 10376 TFA | Neurokinin A(4-10) TFA | Osanetant
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物;
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果;
• 专业团队跟踪*新的制药及生命科学研究进展,为您提供全球*新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。
热门标签:eprazi